Medidata Solutions
announced that Keio Center for Clinical Research (CCR), one of Japan’s two centers of excellence promoting global clinical research, has chosen to standardize on
Medidata Rave
® as its electronic data capture (EDC) and clinical data management (CDM) solution.
Keio CCR was founded in 2006 as an academic research organization within Keio University School of Medicine under the auspices of the Ministry of Health, Labor and Welfare (MHLW) to assume a role in the national improvement of clinical trial infrastructure. Designated by the MHLW in 2009 as one of two centers of excellence to promote global clinical research, Keio CCR plans and supports investigator-initiated, non-NDA clinical trials and observational clinical research, as well as industry-sponsored translational research, registration trials and post-marketing studies.
“Medidata Rave will be key to supporting our strategy of facilitating high-quality clinical research while looking to deliver optimum treatments and improve patient welfare,” said Keio University Center for Clinical Research Professor Yuji Sato MD., PhD.
Keio CCR is upgrading its EDC solution in order to continue to expand, accelerate and improve the quality of its multinational and multicenter clinical studies. Medidata Rave’s investigator-friendly system, which was originally developed for academic clinical trials, will enable Keio CCR to continue to grow its clinical research capabilities.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.